Paper Details

  1. Home
  2. Paper Details

Strontium-89 in palliative treatement of painfull bone metastases.

Author: BirkenfeldBozena, ZorgaPiotr

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Strontium-89 therapy effectively reduced pain in patients with painful osseous metastases, with a response rate of 74%. It was associated with mild transient haemotoxicity, observed in 48% of patients.
Paper Details　
Original Abstract of the Article :
Background. Bone metastases are observed in 30-70% of patients with cancer. Pain is most frequent symptom that requires regular control and treatment. Systemic palliative radionuclide therapy using beta-emitters is alternative method for analgetic drugs and external beam radiotherapy. The aim of the...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/18034034

データ提供：米国国立医学図書館（NLM）

Strontium-89: A Lifeline for Painful Bone Metastases

Cancer is a devastating disease, and bone metastases can add a layer of unbearable pain to the patient's experience. This study investigated the efficacy and safety of strontium-89 (Sr-89) therapy, a radionuclide treatment, in alleviating pain associated with bone metastases.

Easing the Burden: Strontium-89 Offers Pain Relief

The study revealed that Sr-89 therapy was effective in reducing pain associated with bone metastases. A significant percentage of patients experienced a significant reduction in pain, with a very good response observed in 18% of patients and a good response in 46%. While transient haemotoxicity was observed in some patients, the severity was generally mild and manageable. This suggests that Sr-89 therapy offers a valuable palliative option for patients suffering from painful bone metastases, providing relief and improving their quality of life.

A Ray of Hope for Cancer Patients

This research brings hope to patients facing the challenges of painful bone metastases. Sr-89 therapy offers a potential solution to alleviate pain and improve quality of life. However, as with any treatment, careful monitoring is crucial to manage potential side effects. It's like the desert, where even the most resilient camels need careful guidance to navigate its challenges.

Dr. Camel's Conclusion

In the harsh landscape of cancer treatment, finding ways to alleviate pain is like discovering a precious oasis in the desert. Strontium-89 therapy offers a ray of hope for patients battling painful bone metastases. It's a reminder that even in the face of adversity, medical science continues to provide new tools to improve patient care and offer solace in the journey of healing.
Date :
  1. Date Completed 2012-10-02
  2. Date Revised 2007-11-23
Further Info :

Pubmed ID

18034034

DOI: Digital Object Identifier

11356

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.